In the Press
Tuesday, March 20, 2018To Move Paris Accord Forward, Bring Cities and Companies On Board—A Commentary by Daniel C. Esty ’86 and Peter Boyd Yale Environment 360
Monday, March 19, 2018Hype for the Best The New Republic
Friday, March 16, 2018Human Rights Are Not Enough: We must also embrace the fight against economic inequality.—A Commentary by Samuel Moyn The Nation
Thursday, March 15, 2018Justice Scalia’s Fading Legacy—A Commentary by Linda Greenhouse ’78 MSL The New York Times
Tuesday, November 21, 2017
James Geraghty ’80 Appointed Chairman of Pieris Pharmaceuticals Board
Pieris Pharmaceuticals Inc announced that James Geraghty ’80 has been appointed Chairman of the Board of Directors.
Pieris Pharmaceuticals is a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin(R) technology platform for cancer, respiratory and other diseases. The President and CEO of Pieris Pharmaceuticals, Stephen S. Yoder, said, "Jim's proven track record of success and deep experience in the biopharmaceutical industry will be instrumental in guiding Pieris through its next chapter of development, particularly as we advance PRS-343, our proprietary lead immuno-oncology program, into later stage development."
Jim Geraghty has served as member of the Pieris Board of Directors since May 2017 and is an industry leader with thirty years of strategic and leadership experience, including more than twenty years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. Mr. Geraghty was most recently an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture and company-formation fund, and previously served as Senior Vice President, North America Strategy and Business Development at Sanofi, which he joined upon its acquisition of Genzyme. Mr. Geraghty spent twenty years at Genzyme, where his roles included Senior Vice President International Development, President of Genzyme Europe, and General Manager of Genzyme's cardiovascular business. Mr. Geraghty is Chairman of the Board of Idera Pharmaceuticals and Juniper Pharmaceuticals and serves on the Board of Voyager Therapeutics and Fulcrum Therapeutics. He is also a member of the BIO Ventures for Global Health Board of Directors. He started his career in healthcare strategy consulting at Bain and Company. A graduate of the Yale Law School, Mr. Geraghty holds an M.S. from the University of Pennsylvania and a B.A. from Georgetown University.